Table 1.
Baseline Characteristics of Study Subjects, including subgroups.
| Sex: | HIV-1 RNA | |||||||||||
| N | Age | M:F | CD4+ | Duration of Infectiona | CDC Stage C3b | ADC Stage | QNPZ-4 Score | Plasma | CSF | P-C log10 Diff. | CSF WBC | |
| (yrs) | (ratio) | (cells/mm3) | (mean yrs +/- SD) | (percent) | (log10RNA copies/mL) | (cells/mm3) | ||||||
| Total | 100 | 39.0 (36.0–45.0) | 91:9 | 181.5 (48.8 – 285.3) | 9.7 (+/- 5.60) | 70.3% | 0 (0 – 1) | -0.50 (-1.53 – 0.21) | 4.73 (3.52 – 5.15) | 2.74 (1.48 – 4.00) | 1.30 (0.19 – 2.32) | 1.0 (0.0 – 4.0) |
| ADC ≥ 1 = 30.0% | ||||||||||||
| Subdivision by Treatment Group and Effect | ||||||||||||
| Off Treatment | ||||||||||||
| 46 | 38.0 (33.5 – 43) | 42:4 | 195.0 (33.5 – 307.5) | 7.5 (+/- 5.80) | 65.2% | 0 (0 – 0.5) | -0.46 (-1.35 – 0.26) | 4.93 (4.53 – 5.49) | 3.61 (2.57 – 4.40) | 1.19 (0.42 – 21.7) | 2.0 (0 – 11.3) | |
| ADC ≥ 1 = 23.1% | ||||||||||||
| On Treatment (Total) | ||||||||||||
| 54 | 43.0 (38.0-29.3) | 49:5 | 181.5 (76.0 – 275.5) | 11.09 (+/- 5.08) | 75.9% | 0.5 (0 – 1.0) | -0.51 (-2.62 – 0.20) | 3.40 (1.85 – 4.80) | 1.66 (1.28 – 3.07) | 1.37 (0.0 – 2.42) | 1.0 (0.0 – 2.0) | |
| ADC ≥ 1 = 36.6% | ||||||||||||
| On Treatment Failures | ||||||||||||
| 36 | 40.0 (38.0 – 47.8) | 32:4 | 166.5 (48.3 – 276.5) | 11.24 (+/- 4.18) | 75.0% | 0.5 (0 – 1.0) | -0.42 (-2.40 – 0.25) | 4.73 (3.99 – 5.04) | 2.45 (1.45 – 3.64) | 2.19 (1.29 – 2.59) | 0.5 (0.0 – 2.8) | |
| ADC ≥ 1 = 37.0% | ||||||||||||
Values are medians with IQR in parentheses beneath, unless noted. P-Clog10 Diff. is the difference in plasma and CSF log10 HIV concentrations.
aData available for 49 of the 100 subjects.
bData available for 81 of the 100 subjects; categorization based on the 1993 Centers for Disease Control HIV classification system.